Kent David M, McGrath Donnie, Ioannidis John P A, Bennish Michael L
Division of Clinical Care Research, Department of Medicine, Tufts-New England Medical Center, Boston, Massachusetts 02111, USA.
Clin Infect Dis. 2003 Jul 1;37(Suppl 1):S13-24. doi: 10.1086/375368.
The delivery of antiretroviral therapy in the developing world requires guidelines for the appropriate monitoring of therapy, including monitoring for treatment effectiveness and treatment failure, drug toxicities, adherence to therapy, and the emergence of resistant organisms. Guidelines developed in wealthy industrialized countries, which rely heavily on laboratory tests often unavailable in the developing world, may not be feasible or appropriate for resource-limited settings. Even if the standard of care routinely delivered in industrialized settings cannot be replicated, antiretroviral treatment programs with less-intense monitoring have the potential to reduce morbidity and mortality from human immunodeficiency virus. Research to identify monitoring strategies that provide the greatest benefit to those living with human immunodeficiency virus in resource-limited settings and that use the available technologies and resources needs to be conducted within a conceptual and ethical framework that takes into account differences between rich and poor countries.
在发展中世界提供抗逆转录病毒疗法需要有关适当监测治疗的指南,包括监测治疗效果和治疗失败情况、药物毒性、治疗依从性以及耐药生物体的出现。在富裕的工业化国家制定的指南严重依赖发展中世界往往无法获得的实验室检测,可能不适用于资源有限的环境。即使无法复制工业化环境中常规提供的护理标准,但监测强度较低的抗逆转录病毒治疗方案仍有可能降低人类免疫缺陷病毒导致的发病率和死亡率。需要在一个考虑到富国和穷国差异的概念和伦理框架内开展研究,以确定能为资源有限环境中感染人类免疫缺陷病毒者带来最大益处且使用现有技术和资源的监测策略。